Biotech Values

[rfj1862]

but the HTN market didn't reach that point after the first pretty effective drug was approved. Once you had multiple drugs in multiple classes even then there was innovation - ARBs aren't any more effective than ACE inhibitors, but they became mega blockbusters simply because of the adverse event profile (ARB = no risk of cough basically)

It reached that point when the first ARB went generic, after that innovation died in the HTN space.

I had the [dis]pleasure of working on one of the last branded ARBs that was somewhat better than predecessors but it was completely pointless.

If VKTX's drug works as well as it promises, that's an ARB-like event for NASH.

Anyway thanks to Dew I feel better about the patent issue. Not my main area of expertise obviously.